NCT00491816View on ClinicalTrials.gov

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2017

Conditions
Breast Cancer
Interventions
DRUG

Erlotinib with neoadjuvant chemotherapy

150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Kansas Medical Center

OTHER